Hanmi Pharm acquires world’s first approval of combination drug for treatment of both asthma and allergic rhinitis

Published: 2017-05-19 16:26:00
Updated: 2017-05-19 13:55:35

Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kown) announced on the 17th that it acquired commercialization approval of ‘Monterizine,’ a combination drug for patients with both asthma and allergic rhinitis(allergic rhinitis symptom relief), from the Ministry of Food and Drug Safety(MFDS).

Monterizine...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean





TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.